Six-Week Randomized Controlled Trial To Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients

This study compared the plasma amprenavir pharmacokinetics of the human immunodeficiency virus (HIV) protease inhibitors amprenavir (Agenerase) 1,200 mg twice daily (BID) and the amprenavir prodrug GW433908, a formulation that substantially reduces the number of tablets per dose compared with ampren...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Wood, Robin, Arasteh, Keikawus, Stellbrink, Hans-Jürgen, Teofilo, Eugenio, Raffi, François, Pollard, Richard B., Eron, Joseph, Yeo, Jane, Millard, Judith, Wire, Mary Beth, Naderer, Odin J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2004
Assuntos:
Antiviral Agents
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC310156/
https://ncbi.nlm.nih.gov/pubmed/14693528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.48.1.116-123.2004
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados